421 results about "Blood test" patented technology

A method of calibrating glucose monitor data includes collecting the glucose monitor data over a period of time at predetermined intervals. It also includes obtaining at least two reference glucose values from a reference source that temporally correspond with the glucose monitor data obtained at the predetermined intervals. Also included is calculating the calibration characteristics using the reference glucose values and corresponding glucose monitor data to regress the obtained glucose monitor data. And, calibrating the obtained glucose monitor data using the calibration characteristics is included. In preferred embodiments, the reference source is a blood glucose meter, and the at least two reference glucose values are obtained from blood tests. In additional embodiments, calculation of the calibration characteristics includes linear regression and, in particular embodiments, least squares linear regression. Alternatively, calculation of the calibration characteristics includes non-linear regression. Data integrity may be verified and the data may be filtered.

The invention provides a system for monitoring a patient that includes: 1) a first database that stores the patient's blood test information; 2) a monitoring device that collects the patient's cardiovascular and exercise information; 3) a second database that receives cardiovascular and exercise information from the monitoring device; and 4) an Internet-based system that displays the blood test, cardiovascular, and exercise information.

Devices and methods for performing a point of care blood, cell, and/or pathogen count or a similar blood test. Disclosed herein are systems that can be used to provide rapid, accurate, affordable laboratory-quality testing at the point of care. The systems described herein are capable of imaging and counting individual cells in a prepared cell sample (e.g., a peripheral blood smear or a blood sample prepared in a microfluidic device) or another prepared cell-containing sample without the need for a microscope or other expensive and cumbersome optics. The systems described herein are designed to eliminate or replace expensive, centralized clinical testing equipment and technical personnel. Such systems may include automated data reporting and decision support.

Methods and devices for isolating and diagnosing disease with a cell adhesion matrix system, mimicking a metastatic, cardiovascular or placental environment, are disclosed. The cell adhesion matrix facilitates the enrichment of target cells such as metastatic tumor cells, fetal cells and endothelial progenitor cells from a fluid sample such as blood for diagnostic and therapeutic applications in treating patients afflicted with disease, such as cancerous, cardiovascular and fetal diseases, as well as for research applications in molecular analysis of metastatic, and cardiovascular and fetal diseases. Blood test prototypes and methods for the cell enrichment and detection of circulating tumor and endothelial cells using multiplex molecular analysis are described herein. In addition, methods and compositions for determining host immunity to tumor in subjects with risk of cancer progression and methods for isolating an enriched fraction of fetal cells from pregnant females for prenatal diagnosis are also described herein.

Amplification and overexpression of theHER-2 oncogene in breast cancer is felt to be stable over the course of disease and concordant between the primary tumor and metastases. Therefore, patients with HER-2 negative primary tumors will rarely receive anti-HER-2 antibody therapy. A very sensitive blood test is used to capture circulating tumor cells (CTC's) and evaluate their HER-2 gene status by FISH evaluation. The HER-2 status of the primary tumor and corresponding CTC's is used to assess the ratio of CTC's as a reliable surrogate marker. HER-2 expression of 10 CTC's is sufficient to make a definitive diagnosis of the HER-2 gene status for the whole population of CTC's in patients with recurrent breast cancer.

The present invention is a Miniature Vein Enhancer that includes a Miniature Projection Head. The Miniature Projection Head may be operated in one of three modes, AFM, DBM, and RTM. The Miniature Projection Head of the present invention projects an image of the veins of a patient, which aids the practitioner in pinpointing a vein for an intravenous drip, blood test, and the like. The Miniature projection head may have a cavity for a power source or it may have a power source located in a body portion of the Miniature Vein Enhancer. The Miniature Vein Enhancer may be attached to one of several improved needle protectors, or the Miniature Vein Enhancer may be attached to a body similar to a flashlight for hand held use. The Miniature Vein Enhancer of the present invention may also be attached to a magnifying glass, a flat panel display, and the like.

An analysis element for use in a blood test method enabling easy and simple operations that are performed quickly up to measurement, an analysis element for use in a blood test method that operations up to the measurement for many components can be quickly performed, and that is safe and has a sufficient measurement accuracy thereof, and an analysis element for use in a test method using body fluids and urines of humans and animals, plain water, seawater, soil extract, agricultural products, marine products, processed-food extracts, and liquid for use in scientific research as specimens, are provided, the present invention relates to a multi-component measurement dry analysis element for use in a method for testing a specimen, the method using an area sensor as a detector to obtain a result of measurement according to information represented by 1000 pixels or more per one component, and to perform simultaneous measurements of plural components.

Differential Methylation Hybridization (DMH) was used to identify novel methylation markers and methylation profiles for hematopoieetic malignancies, leukemia, lymphomas, etc. (e.g., non-Hodgkin's lymphomas (NHL), small B-cell lymphomas (SBCL), diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL), mantle cell lymphoma (MCL), B-cell chronic lymphocytic leukemia/small lymphocytic lymphoma (B-CLL/SLL), chronic lymphocytic leukemia (CLL), multiple myeloma (MM), acute myelogenous leukemia (AML), acute lymphoblastic leukemia (ALL), etc.). Particular aspects provide novel biomarkers for NHL and subtypes thereof (e.g., MCL, B-CLL/SLL, FL, DLBCL, etc.), AML, ALL and MM, and further provide non-invasive tests (e.g. blood tests) for lymphomas and leukemias. Additional aspects provide markers for diagnosis, prognosis, monitoring responses to therapies, relapse, etc., and further provide targets and methods for therapeutic demethylating treatments. Further aspects provide cancer staging markers, and expression assays and approaches comprising idealized methylation and/or patterns” (IMP and/or IEP) and fusion of gene rankings.

Immunosorbents, kits and compositions for diagnosing a central nervous system disorder, particularly paroxysmal cerebral discharges and epilepsy, comprising measuring the concentration of GluR1 or fragment thereof and/or GluR1 antibodies in a biological sample from a human subject. The method is particularly useful for identifying individuals that are at risk for brain related seizures and epilepsy, for distinguishing epilepsy from pseudo-epilepsy and epilepsy-like disorders, for following up after anticonvulsive treatment, and for the adjustment of adequate therapy and doses.

A blood collection device adapted to receive a multi-component blood sample is disclosed. After collecting the blood sample, the blood collection device separates a plasma portion from a cellular portion. After separation, the blood collection device is able to transfer the plasma portion of the blood sample to a point-of-care testing device. The blood collection device of the present disclosure also provides a closed collection and transfer system that reduces the exposure of a blood sample and provides fast mixing of a blood sample with a sample stabilizer. The blood collection device is engageable with a blood testing device for closed transfer of a portion of the plasma portion from the blood collection device to the blood testing device. The blood testing device is adapted to receive the plasma portion to analyze the blood sample and obtain test results.

A method of measuring a hemoglobin parameter of a test sample of blood comprises diluting and lysing a test sample. Then, a temperature corresponding to the test sample is obtained. The diluted and lysed test sample is then delivered to a cuvette, and a spectrophotometer determines the absorbance and/or transmittance of the sample in the cuvette. With the absorbance and/or transmittance of the test sample, a first measurement of the hemoglobin parameter of the test sample is obtained. After a first measurement of the hemoglobin parameter is obtained, a processor determines a corrected measurement of the hemoglobin parameter of the test sample. The corrected measurement is a function of the measured temperature that corresponds to the test sample and the first measurement of the hemoglobin parameter. The method of measuring a hemoglobin parameter is valid over a range of test sample temperatures.

A microchannel array, a method of manufacturing the same, and a blood test method. The microchannel array is formed by joining first and second substrates, each including a fluid inlet and outlet on their surfaces. An internal space structure connects the fluid inlet and outlet, and includes an upstream flow channel connected with the fluid inlet, a downstream flow channel connected with the fluid outlet with a gap therebetween, and a micro flow channel connecting the upstream and downstream flow channels. A minimum distance from a center of a sectional surface of the micro flow channel to a side wall of the micro flow channel is smaller than that of the upstream and downstream flow channels. Each surface of the first and second substrates includes grooves for creating the upstream and downstream flow channels, and the surface of the second substrate has grooves for creating the micro flow channel.

The present invention is a Miniature Vein Enhancer that includes a Miniature Projection Head. The Miniature Projection Head may be operated in one of three modes, AFM, DBM, and RTM. The Miniature Projection Head of the present invention projects an image of the veins of a patient, which aids the practitioner in pinpointing a vein for an intravenous drip, blood test, and the like. The Miniature projection head may have a cavity for a power source or it may have a power source located in a body portion of the Miniature Vein Enhancer. The Miniature Vein Enhancer may be attached to one of several improved needle protectors, or the Miniature Vein Enhancer may be attached to a body similar to a flashlight for hand held use. The Miniature Vein Enhancer of the present invention may also be attached to a magnifying glass, a flat panel display, and the like.